A recent survey conducted by Strupp et al. (2025), analyzed intervention trends across 234 respondents from 47 countries. This survey sought to investigate preferred treatment types for unilateral vestibular dysfunction (UVD), bilateral vestibular dysfunction (BVD), superior canal dehiscence syndrome (SCDS), benign paroxysmal positional vertigo (BPPV), and Meniere’s disease (MD). Across respondents, UVD was most commonly treated pharmacologically with oral steroids, antiemetics, and Betahistine. The second most common treatment choice for UVD was vestibular rehabilitation therapy. BVD was most often treated with vestibular rehabilitation therapy. SCDS was most typically treated surgically thorough a variety of approaches. BPPV was most commonly treated with canalith repositioning, and treatment types were typically canal specific. Finally, MD was often treated with a variety of medications including Betahistine, diuretics, oral steroids, antiemetics, and gentamycin; the second most common treatment for MD was surgical.
These authors noted fairly heterogeneous treatment trends across respondents, regardless of practice location. However, the authors also noted a lack of empirical evidence supporting the efficacy of many of the drugs that were reportedly used for the various vestibular conditions.
Reference
Strupp M, Kern L, Laurell G, Lehner L, Grill E, Strobl R. (2025) World-wide survey on the treatment of peripheral vestibular disorders. Front Neurol 16.
Recent Posts
Mississippi and Missouri Go Live in ASLP Compact
The Audiology & Speech-Language Pathology Interstate Compact (ASLP-IC) continues to expand, with Mississippi officially going live on November 9, and Missouri following on November 16. With…
Senators Merkley and Gillibrand Introduce Professional Student Degree Act
Senators Jeff Merkley (D-OR) and Kirsten Gillibrand (D-NY) have introduced the Professional Student Degree Act in the Senate, companion legislation to H.R. 6718, introduced in the…
CMS Offers States an Optional Pause on Medicaid Work Requirement Enforcement
On November 13, 2026, CMS announced that states may protect otherwise eligible Medicaid applicants and beneficiaries from work-requirement-related coverage denials through June 30, 2027. The…



